Pfizer Announces Enrollment Of First Patient In Phase 3 Trial In Sickle Cell Disease

1 min read

The FINANCIAL — Pfizer Inc. on June 23 announced that the first patient has been enrolled in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study – a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis in hospitalized individuals with sickle cell disease who are six years of age or older.

Sickle cell disease is one of the most prevalent genetic disorders in the U.S. It is a rare and debilitating chronic disease with lifelong clinical impact and reduced life expectancy; life expectancy is 48 years for females and 42 years for males with sickle cell disease. There are more than 100,000 people in the U.S. living with sickle cell disease1, and many of them experience multiple vaso-occlusive crises each year. These painful crises result in more than 75,000 hospitalizations per year in the U.S., with an average hospital stay of approximately six days.

“Scientific innovation cannot forge ahead without the patients that are willing to work with the scientific community by participating in clinical trials,” said Sonja L. Banks, president and chief operating officer of the Sickle Cell Disease Association of America. “Patients should speak with their healthcare providers if they are interested in learning more about how to participate in a trial.”

 

Leave a Reply